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Summary: In vivo effects of reversible inhibitors of cholinesterase activity were determined radiometrically in
undiluted samples of erythrocytes and plasma. [14C]acetylcholine at substrate saturation, 25 °C and pH 7.4
permitted rapid and precise determination of butyrylcholinesterase (EC 3.1.1.8) and acetylcholinesterase (EC
3.1.1.7) activities. Reference values for acetylcholinesterase and butyrylcholinesterase were estimated in the
plasma and erythrocyte haemolysate of 102 healthy volunteers.
The time course of in vitro inhibition was monitored, starting immediately after addition of 9-amino-l,2,3,4-
tetrahydroacridine (tacrine), eserine or pyridostigmine to undiluted human plasma. Maximal inhibition (in
vitro) was seen within 60 min with tacrine and eserine, in contrast to 180min with pyridostigmine. The
inhibition remained constant for more than 10 h except with eserine, from which enzyme activity showed an
early recovery. Concentration response experiments were performed in undiluted human plasma and undiluted
human erythrocyte haemolysate. /^-values of tacrine, eserine and pyridostigmine were estimated. In contrast
to pyridostigmine and eserine, tacrine was found to have a higher affinity for butyrylcholinesterase than for
acetylcholinesterase. Tacrine at 2.5 μηιοΐ/ΐ resulted in complete inhibition of butyrylcholinesterase and 70%
inhibition of acetylcholinesterase activity. Dilution of these samples up to 100-fold was accompanied by
almost complete recovery of acetylcholinesterase and by 50% recovery of butyrylcholinesterase.
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. t- . ί j ^ ase (EC 3.1.1.7) in erythrocytes without prior dilution,beneficial or adverse effects.
Esterase determination in the traditional way requires
dilution of plasma or erythrocyte haemolysate. But Materials and Methods
the dilution may cause reactivation of the cholines- pr incipie Of the procedure
terases, which have been inhibited reversibly by po-
 f. J . , , . . , . , _ .
A A. , A, · ι ι ,A r\ τ j Acetylcholme, radiolabelled m the acetyl moiety, is split by thetential therapeutical substances (4, 5). In order to
 enzyme reaction at 25 ^  pH 7 4 and at substrate saturation;
measure true the inhibition, as present in vivo, it is the reaction is stopped by ethanol/glacial acetic acid, and the
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labelled acetic acid released by the esterase activity is evapo-
rated, while labelled acetylcholine which has not been hydro-
lysed remains in the sample and can be measured. The decrease
in radioactivity in the evaporated aliquots is proportional to
the enzyme activity.
Substrate consumption serves as a measure of enzyme activity.
Since reaction velocity remains constant (zero order reaction)
only at substrate saturation, the reaction must be stopped
before the decreasing substrate concentration leads to a first
order reaction. Therefore, the linearity of the enzyme reaction
was checked in relation to the incubation period and appro-
priate time intervals were established for the measurements. In
agreement with previous authors (6, 7), a satisfactory correla-
tion was found down to 50% of the initial substrate concen-
tration.
Chemicals, radioact ive compounds, drugs
All chemicals were commercially available and of the highest
available degree of purity. [14C]acetylcholine-iodide is a product
of NEN, Boston, U. S. A. Eserine and tacrine were provided
by SERVA, Heidelberg, F. R. G., pyridostigmine is a product
of ROCHE, Grenzach-Wyhlen, F. R. G.
Prepara t ion of samples
Human plasma and erythrocytes were obtained from healthy
male and female volunteers by venepuncture of the elbow.
Coagulation was prevented by crystalline heparine; whole blood
was centrifuged for 10 minutes at 2200 g and the plasma drawn
off with a pipette. Erythrocytes were haemolyzed by freezing
three times in liquid nitrogen and thawing. Samples were ad-
justed to pH 7.4 prior to incubation.
Incubat ion procedure
In an Eppendorf micro test tube, 10 μΐ of substrate solution
were added to 100 μΐ of sample material, blended immediately
for 10 seconds with a mixer and subsequently incubated at
25 °C while being shaken in a water bath (Thermomix 1460,
Braun-Melsungen, F. R.G.). Substrate concentrations were 10
mmol/I for butyrylcholinesterase and 4 mmol/1 for acetylcholin-
esterase in erythrocytes. [14C]acetylcholine-iodide was added to
yield a specific ratioactivity of 167 kBq/mmol for the butyryl
cholinesterase and of 407 kBq/mmol for the acetylcholinester-
ase. One sample with 100 μΐ buffer without enzyme was used
to determine the nonenzymatic hydrolysis. The enzyme activity
was stopped by the addition of 1 ml of 2 g/1 glacial acetic acid
in ethanol, volume fraction 0.98.
Samples were mixed immediately and centrifuged for 5 minutes
at 10000#. From the supernatant, 2 aliquots of 400 μΐ each
were taken from erythrocyte samples and 500 μΐ from plasma
samples and transferred to counting vials (blank and sample).
The initial value for each sample was determined directly from
the first aliquot. The second aliquot was diluted with another
500 μΐ of glacial acetic acid and subsequently taken completely
to dryness in a Speed Vac Concentrator (Bachofer, Reutlingen,
F.R.G.).
After evaporation of free acetic acid, the concentrated aliquots
were diluted with distilled water and scintillation fluid, using
the same quantities as were added to the directly measured
aliquots. They were subsequently shaken twice for 10 seconds
to ensure complete mixing of the radioactivity with the scintil-
lator.
Measurement of r ad ioac t iv i ty
All samples were carefully dissolved in 1 ml H2O as well as 10
ml of a scintillator mixture composed of 100 g naphtalene, 10 g
2.5 diphenyloxazole (PPO), 0.25 g 1.4 bis-(2-4-methyl;-5- phen-
oxazolyl) (POPOP) with 11 dioxan and measured in a beta-
counter (RackBeta Spektral 1219, LKB).
The difference of radioactivity between dried and non-dried
aliquots is the index enzyme activity after subtraction of the
nonenzyraatic hydrolysis. Enzyme activity (μτηοΐ/min -I) can be
calculated from the specific radioactivity (Bq/mmol) of the
substrate applied, the incubation time and the amount of
plasma and erythrocytes used.
Results
Precision of the method
The precision of the measuring method was tested by
multiple determinations. The 20-fold determination
of a sample within one day yielded a variation coef-
ficient (CV) of 3.5% in human plasma and 4.5% in
human erythrocyte haemolysate.
Plasma and erythrocyte samples from healthy test
subjects were used to test the reproducibility on dif-
ferent days. Variation coefficients of 4.7% and 7.5%
respectively were determined for a time span of 14
days.
Linearity of the enzyme reaction
The multiple determinations for linearity testing were
individually evaluated, and the activity was plotted
as difference of radioactivity against incubation time.
Enzyme activity correlated well with time until almost
50% of the substrate had been hydrolysed. Results
are shown in figures 1 a and 1 b. It can be seen that
the incubation intervals used for ordinary testing, 120
seconds for plasma and 15 seconds for erythrocytes,
are well in the linear range.
Reference values
Blood samples for the estimation of acetyl- and bu-
tyrylcholinesterase activities were obtained from the
staff of a university hospital, Klinikum Steglitz, Freie
Universit t Berlin, on the occasion of a medical ex-
amination routine. 102 male and female volunteers
took part, with an age of 16 to 57 years, without
obvious illnesses and without intake of drugs, 14 days
prior to investigation. The use of oral contraceptives,
however, was no exclusion criterion but separately
monitored. The median age of the females was 32
(range 16—57 years) and the median age of the males
31 (range 20 — 55 years).
The reference samples were evaluated according to
Stamm (14). Butyrylcholinesterase activities of 2.05
± 0.40 (kU/1) with a range of 1.34-2.77 (kU/1) for
males and 1.92 ± 0.40 (kU/1) with a range of 1.15-
2.71 (kU/1) for females were estimated. The acetyl-
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Time course of choli nest erase activity in human plasma
(a) and acetylcholinesterase activity in human erythro-
cyte haemolysate (b). Five estimations (+ ) at each time
interval. Correlation coefficient of 0.9956 (plasma) and
0.9637 (erythrocytes) calculated from values below 50%
of the initial substrate concentration. The arrow marks
the standard incubation time of the subsequent experi-
ments.
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Fig. 2. Frequency distribution of the enzyme activities of bu-
tyrylcholinesterase (a) and acetylcholinesterasc (b) in
the volunteer panel. 102 values are shown as histograms;
the line represents the respective Gaussian curve of the
data with a cut-off value of 1.0 (kU/1) in fig. 2 a and
3.5(kU/l)inflg.2b.
cholinesterase activity was calculated as 6.14 ± 0.95
(kU/1) with a range of 3.93-8.25 (kU/1) for males
and 6.00 ±1.18 (kU/1) with a range of 3.80-8.36
(kU/1) for females.
The enzyme activities of acetylcholinesterase and bu-
tyrylcholinesterase were bimodally distributed. A first
maximum of distribution was seen at 0.80 and at 2.60
(kU/1) for the butyryl- and the acetylcholinesterase,
respectively, and these were not the same individuals.
Similar findings have been reported (8) for serum
paraoxonase, but not yet for cholinesterases. With a
cut-off value of 1.0 (kU/1) for the butyrylcholinester-
ase and 3.5 (kU/1) for the acetylcholinesterase, the
frequency distribution was normal and the data could
be well described with a Gaussian curve (fig. 2a +
b). The means, standard deviations and ranges of the
normal values of the butyrylcholinesterasc activity
were comparable to the findings of other authors, as
shown in table 1.
Tab. 1. Comparison of normal values of butyrylcholinesterase catalytic activity concentration (kU/1) as reported from various
authors. Substrates used were acetylcholine (our method) and acctylthiocholine (other methods).
n
Mean
SD
Range
Our method
6
36
2.05
0.43
1.3-2.9
9
54
1.92
0.43
1.1-2.8
Other method 1, Prellwitz (12)
c? ?
226 198
2.43 2.20
0.68 0.51
1.3-3.7 1.2-3.2
Other method 2, Huizenga (9)
<ί 9
36 41
3.11 2.50
0.57 0.43
1.8-4,4 1.6-3.5
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The butyrylcholinesterase activity was lower in fe-
males than in males, as already reported by various
authors (9-11). In the present work, this difference
was not statistically significant, and the data are in
accordance with the work of Prellwitz et al. ((12), tab.
1). No statistically significant differences were seen in
the acetyl- and butyrylcholinesterase activities be-
tween women who were (n = 16) and those who were
not (n = 45) using oral contraceptives; this finding
has already been published elsewhere for
butyrylcholinesterase (11). In 10 brain areas of 23
men and 22 women post mortem, Kewitz et al. found
no significant differences between sexes for the ace-
tylcholinesterase activity (13).
Stabili ty of the samples
The time course of inhibition by the inhibitors was
determined in vitro in order to see whether enzyme
activity recovers during the time interval of the ex-
perimental procedure. No relevant recovery was
found in human plasma within 10 hours at 25 °C with
tacrine (fig. 3 a) or pyridostigmine (fig. 3 c), whereas
a relevant/significant (concentration dependent) re-
covery was seen with eserine (fig. 3 b). The storage of
plasma samples for up to 28 days at —20 °C led to
no significant change of enzyme activity, which agrees
with the findings of other authors (11, 18).
Kinetics of i n h i b i t i o n
The kinetics of esterase inhibition were determined in
vitro at 25 °C immediately after various inhibitors at
different concentrations had been added. The time
interval for maximal inhibition was markedly longer
at lower concentrations. The time intervals for prein-
cubations in the subsequent concentration-response
tests were accordingly adjusted and kept constant in
all experiments. Preincubation periods were 60 min-
utes with eserine or tacrine and 90 minutes for pyri-
dostigmine. Inhibition by tacrine and pyridostigmine
remained constant at 25 °C over a period of about 10
hours. An early recovery was seen with eserine, es-
pecially at lower concentrations. These findings are
shown in figures 3 a—c.
Concentration-response curves
Concentration-response relations with acetylcholin-
esterase of human erythrocytes showed ATrvalues of
14 nmol/1 with eserine, 300 nmol/1 with pyridostigmine
and 630 nmol/1 with tacrine. For butyrylcholinester-
ase, the ^-values were 21 nmol/1 with eserine, 98
nmol/1 with tacrine and 760 nmol/1 with pyridostig-
mine. Concentration-response curves are shown in
figures 4 a and 4b, Krvalues in table 2.
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Fig. 3. Time course of enzyme inhibition in vitro (human
plasma) by various inhibitors at different concentra-
tions.
a) 1, 0.1, 0.01 μηιοΐ/l tacrine,
b) 1, 0.1, 0.01 μιήοΐ/ΐ eserine,
c) 10, 1, 0.1 μηιοΙ/1 pyridostigmine.
Effects of dilution
Tacrine was added to human plasma or erythrocytes
in a final concentration of 2.5 μιήοΐ/ΐ. These samples
were then diluted up to 100-fold. Recovery of enzyme
activity was related to concentration, and in the case
of acetylcholinesterase, recovery was nearly 100% at
100-fold dilution; at a similar dilution, the recovery
of butyrylcholinesterase amounted to only 50%. Re-
sults of these tests are shown in figures 5 a and 5 b.
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Fig. 4. Concentration-response curves of various cholinester-
ase-inhibitors in human plasma (a) or human erythro-
cytes (b). Tacrine (circles), eserine (triangles), pyrido-
stigmine (squares). Preincubation for 60 minutes with
tacrine or eserine and 90 minutes with pyridostigmine
in the absence of substrate at 25 °C. Each value is the
mean of two estimations, pi = ~logto[I].
Fig. 5. Effect of dilution on the recovery of enzyme activity. A
spiked sample of human plasma (a) and erythrocyte-
haemolysate (b) at a concentration of 2.5 μιηοΐ/ΐ tacrine
was preincubated for one hour. Samples were diluted
up to 100-fold before starting the enzyme reaction by
addition of substrate. Reaction period was increased
according to the dilution of enzyme.
Tab. 2. Comparison of the -^rvalues (nmol/1) of eserine, pyri-
dostigmine and tacrine on the butyryl- and acetylcho-
linesterase activities.
Substance
Eserine
Pyridostigmine
Tacrine
Butyryl-
dholinesterase
(plasma)
21
760
98
Acetylcholinesterase
(erythrocytes)
14
300
630
Discussion
In principle, the activity of cholinesterases can be
determined by measuring either decrease of substrate
(15 —17) or increase of products. Products are acetic
acid (6, 7, 18-22) and choline (10, 23, 24) or thio-
choline (11, 25—28), if the respective artificial sub-
strate is used.
With few exceptions (16, 17), the methods currently
in use employ considerable dilution. Dilution of the
enzyme, however, is followed by considerable recovery
from inhibition caused by reversible inhibitors. There-
fore to monitor enzyme inhibition, dilution should be
avoided (figs. 5 a and 5b). The method described
fullfils that requirement. The method is rapid, sensi-
tive, precise and needs small amounts of samples only.
The measurement of the substrate consumption can
be used at various substrate concentrations and also
at different pH values and temperatures. Human
erythrocytes show an activity of about 6 · ΙΟ3 μιηοΐ/
min · l (30) which means that 1 ml hydrolyses more
than the substrate concentration at saturation in one
minute if used undiluted. It can be concluded that
enzymatic hydrolysis is zero order in an undiluted
sample for a few seconds only. Winteringham & Dis-
ney (16) in 1962 introduced the measurement principle
of determining the cholinesterase activities in undi-
luted materials by means of radiometry of unhydro-
lysed 14C-labelled acetylcholine. The precision of the
method, however, was low and numerous modifica-
tions have been proposed to improve the test.
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In the procedure described in this paper, the pH value
7.4 was chosen to mimic physiological conditions as
closely as possible. Inhibition is pH-dependent; more-
over the increase of nonenzymatic hydrolysis occur-
ring at a more alkaline pH is thus largely prevented.
The temperature of 25 °C is applicable for 90% of
the year and at other times it is slightly above room
temperature in our climate. A lower temperature
would have been favorable but would have required
a more complicated cooling system. A higher tem-
perature, on the other hand, would have reduced the
short incubation time for undiluted samples even fur-
ther. Various authors have stressed the significance of
the preincubation time interval of inhibitors of cho-
linesterases in the absence of substrate for the com-
parability of in vitro experiments (4, 31).
As La Du & Eckerson (8) described for other enzymes,
the acetyl- and butyrylcholinesterase activities of our
volunteer panel represented a bimodal distribution.
Genetic polymorphism might have contributed to this
finding, because our reference panel is not a repre-
sentative part of the population and has not been
screened with regard to heterozygotes or homozygotes
for the atypical enzyme. It is known that phenotypes
are differentiated at 25 °C, which was the standard of
the present examination, more distinctly than at other
incubation temperatures (32). Further investigations
will be performed to verify the data.
From the present findings it may be concluded that
the determination of substrate consumption by radio-
activity measurement permits a rapid and easily re-
producible determination of the acetyl- and butyryl-
cholinesterase activities in undiluted samples. The
method is suitable for estimating the inhibition of
cholinesterases by reversible inhibitors in vivo, and it
is appropriate for monitoring treatment. It is known
from patients with a 'silent gene', who are devoid of
any butyrylcholinesterase activity, that this condition
is not a life threatening factor per se (33). Additionally
there is no correlation between plasma cholinesterase
and erythrocyte cholinesterase, and persons with atyp-
ical plasma cholinesterase have normal erythrocyte
acetylcholinesterase activities (34). Therefore the
monitoring of both enzymes, acetyl- and butyryl-
cholinesterase is needed, particularly within a narrow
therapeutic range.
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